April 26, 2018 / 12:29 PM / 7 months ago

BRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa

April 26 (Reuters) - Krystal Biotech Inc:

* KRYSTAL BIOTECH ANNOUNCES FDA CLEARANCE OF IND ON KB103 TO BEGIN ENROLLING PATIENTS FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

* KRYSTAL BIOTECH INC - PLANNED PHASE 1/2 CLINICAL STUDY OF KB103 IS A SINGLE SITE STUDY AT STANFORD UNIVERSITY EXPECTED TO START IN MAY 2018

* KRYSTAL BIOTECH INC - INITIAL DATA FROM STUDY OF KB103 ARE EXPECTED TO BE RELEASED BY END OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below